NanoImpacts 2026

Name: NanoImpacts 2026
Start: 2026-10-07T22:00:00-0400
End: 2026-10-08T17:00:00-0400

Overview

This two-day conference will bring together academic researchers, students, biotechnology companies, and government partners to explore advances in synthetic biology, DNA computing, microbiome engineering, biosensing, nanobiointerfaces, and biomanufacturing.

By connecting fundamental discoveries with applications in health, agriculture, environmental monitoring, and scalable biological production, NanoImpacts 2026 will strengthen North Carolina’s life sciences ecosystem, create interdisciplinary partnerships, and support workforce development and the translation of research into deployable technologies.

October 7, 2026 10:00pm - October 8, 2026 5:00pm

Joint School of Nanoscience and Nanoengineering
2907 East Gate City Blvd.
Greensboro, North Carolina 27401

No Cost

Bioeconomy
Biomanufacturing

June 9, 2027

4th Annual Cloud Computing Education in Data Science, Genomics and Health Symposia

The symposium serves as a platform for sharing innovative research, fostering interdisciplinary collaborations, expanding professional networks, and strengthening workforce development pathways. It brings together students, faculty, researchers, industry partners, and federal program officers to explore advances in computational genomics, data science, artificial intelligence, and cloud-enabled research.

November 5, 2026

NC A&T: Advancing Undergraduate Biotechnology and Life Sciences Research in NC

The 2026 NC A&T Honors College Research Conference will showcase student scholarship and promote research excellence across various academic disciplines. While the conference welcomes presentations from all academic fields, biotechnology and the life sciences have consistently accounted for a significant share of conference participation.

August 26, 2026

Cambrex cleared to make pharmaceutical ingredients in High Point

Cambrex’s newly expanded pharmaceutical manufacturing facility in High Point has passed three major regulatory hurdles, allowing it to begin commercial production. The company announced the successful completion of three pre-approval inspections of the facility by the U.S. Food and Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency and Australia’s Therapeutic Goods Administration.